Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
208.6 USD | +1.85% | -0.28% | -16.74% |
May. 08 | Morgan Stanley Cuts Price Target on Penumbra to $235 From $240, Keeps Equalweight Rating | MT |
May. 07 | Penumbra Q1 Non-GAAP EPS, Revenue Increase; Reaffirms 2024 Revenue Outlook | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 57% by 2026.
- The company's profit outlook over the next few years is a strong asset.
- The company is in a robust financial situation considering its net cash and margin position.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- With an expected P/E ratio at 74.48 and 54.06 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-16.74% | 7.94B | C+ | ||
+73.51% | 12.4B | B- | ||
-0.66% | 6.17B | C- | ||
+16.74% | 5.55B | D+ | ||
-3.21% | 5.35B | B | ||
+46.20% | 5.03B | - | ||
-17.73% | 4.07B | B- | ||
-29.78% | 2.65B | C | ||
-0.74% | 1.99B | - | ||
+35.97% | 1.93B | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- PEN Stock
- Ratings Penumbra, Inc.